As an IR who practices Interventional Oncology almost exclusively, I have always felt a bit uneasy using the term “Interventional Oncology” with my medical and surgical oncology colleagues.
WCIO took the next step on its mission to enhance global IO education with IO University’s first live webinar. An expert panel discussed the diagnosis and treatment options for malignant ascites.
WCIO kicked off its 2014 season of VuMedi webinars yesterday with the first of three programs devoted to percutaneous tumor ablation. This session focused on lung ablation. Over 85 registrants from North America, South America, and Asia participated live. I was excited to see friends from Brazil and
One of my NP’s presented a new consult to me this week: 15cm central HCC, wheelchair bound, heart and renal failure, blistering wounds on the legs from severe edema requiring daily dressing changes and whirlpool therapy for debridement...you get the picture. She advised me not to treat him.
One of the exciting developments in IO research has been the investment by industry in prospective clinical trials to help define best practice in the care of our patients. Nordion, Merit/Biosphere, Sirtex, BTG/Biocompatibles, Siemens, and Delcath all sponsor multicenter Phase 2 and 3 trials...